Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Matérias relacionadas
Comentários
Deixe um comentário
Todos os campos são requeridosMais vistas
- Presidente do Conselho Nacional Palestino condena decisão judicial israelense em apoio ao bloqueio imposto a Gaza
- Presidente do México descreve como proveitosa a reunião com Kristi Noem
- Marine Le Pen é condenada à prisão e declarada inelegível
- ALBA-TCP adverte sobre a obsessão dos EUA contra povos da região
- Ministro das Relações Exteriores de Cuba denuncia sequestro de migrantes como ato atroz